Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PPJIA2020-15 | Other Grant/Funding Number | Universidad de Granada | |
| PI-0187-2021 | Other Grant/Funding Number | ConsejerÃa de Salud y Familias (Junta de AndalucÃa) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with head and neck cancer post-radiotherapy may improve their perceived and amount of saliva after a 3-month Photobiomodulation (PBM) therapy focuses on three main salivary glands (parotid, submandibular and sublingual glands).
The use of PBM therapy in survivors with head and neck cancer may be an effective treatment to improve xerostomia and hyposalivation as side effects of radiotherapy. Although there is some scientific evidence on its benefits during or after radiotherapy, it is not sufficient to establish it as an effective treatment. For these reasons, studies of higher methodological quality such as randomized controlled trials, are needed. This study aims to demonstrate the benefits of PBM therapy on xerostomia and hyposalivation in survivors with head and neck cancer undergone radiotherapy, and whether the effects are maintained after a follow-up period.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PBM group | Experimental | Energy density 7.5 J / cm2 |
|
| Control group | Placebo Comparator | The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective goggles) using the same laser device to imitate a real irradiation; however, the device will be turned off and recording of the emission sounds will be used to give the patient the hearing sensation of the PBM therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Energy density photobiomodulation (7.5) | Device | A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Xerostomia severity. | Xerostomia Inventory consists of 11 items, the total score ranges from 11 to 55 points, and represents the severity of chronic xerostomia. Higher scores mean a worse outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Salivary flow rate. | Determines the amount of unstimulated saliva (ml) produced in 3 minutes. Higher amount means less hyposalivation. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| General and specific quality of life in patients with head and neck cancer. | The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0 assesses overall quality of life. It is a valid questionnaire and widely used in cancer population. High score for functional scales and global health status represents better outcomes. Higher symptom scales/items scores mean a worse outcome. In addition, its specific head and neck module (EORTC QLQ-H&N35) where higher symptom scales/items scores mean a worse outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Nutritional and oral status. | Assesses through a Eating Assessment Tool questionnaire (EAT-10). Higher scores mean a worse outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Maximum mouth opening. | Determine maximum mouth opening (mm) as the inter-incisor distance using a sliding caliper. More distance means better mobility. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Measure | Description | Time Frame |
|---|---|---|
| Pressure pain threshold. | Using a digital algometer in C5-C6 joint, upper trapezius, levator scapulae, masseter, temporalis, sternoclavicular joint and the tibialis anterior (distal point). Higher values mean higher pain pressure threshold. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and adverse events | Each adverse event is characterized by severity (grade 1 [mild] to 5 [death]), expectation (expected or unexpected) and potential relationship with participation in our study (unrelated, possibly related, or related to the study) using Common Terminology Criteria for adverse events (version 5.0). Higher scores mean a worse outcome. | 12 weeks (after intervention). |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Noelia Galiano-Castillo, PhD | Universidad de Granada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Health Sciences | Granada | 18016 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41013422 | Derived | Lopez-Garzon M, Plata-Peregrina MDC, Perez-Sanchez EI, Lozano-Lozano M, Artacho-Cordon F, Galiano-Castillo N. Photobiomodulation for restoring salivary flow after radiotherapy in head and neck cancer: a randomised placebo-controlled trial. BMC Oral Health. 2025 Sep 26;25(1):1468. doi: 10.1186/s12903-025-06735-3. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D014987 | Xerostomia |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
Randomized controlled trial
Not provided
Not provided
Participants who meet the inclusion and exclusion criteria will be randomized to one of the two study groups using a random number generation program (www.randomizer.org). The randomization sequence will be prepared by a member external to the investigation to respect the masking in terms of randomization of the participants, thus reducing the risk of bias during the evaluations. Therefore both patients and evaluator will be masked.
| Sham placebo | Device | A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). |
|
| Fitness Scale. |
The International Fitness Scale (IFIS) assesses overall fitness, cardio-respiratory, muscular, speed and flexibility dimensions using a 5-point Likert scale ('very poor', 'poor', 'average', 'good' and 'very good'). Higher scores mean a better outcome. |
| Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Mood status. | The Spanish version of the Scale for Mood Assessment (EVEA) assesses mood state with a range of 0 to 10. It consists of 4 subscales: sadness-depression, anxiety, anger-hostility and happiness. Higher scores mean a worse outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Quality of sleep. | The Pittsburgh Sleep Quality Index will be used to evaluate the perceived quality of sleep in its Spanish version. Higher scores mean a worse outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Physical activity level. | The International Physical Activity Questionnaire (IPAQ-SF) is a tool that it will be used to evaluate physical activity. Different types of physical activities will be recorded (walking, moderate intensity activities, and vigorous intensity activities) during the last 7 days. More time means more amount of physical activity. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Functional capacity. | Using walked distance (m) during 6-minutes walking test. Longer distance means better outcome. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Risk of falls. | Using time (s) during Test Up and Go (TUG). Less time means less risk of falls. | Change from Baseline to 12 weeks (after intervention) and to 6 months (follow-up). |
| Satisfaction questionnaire. | Each patient will mark his/her experience after PBM therapy. Higher scores mean a better outcome. | 12 weeks (after intervention). |